Business Context and Reporting Period
Company: Spectral AI, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 18, 2026
Reporting Period: Event-based (March 18, 2026)
Business Overview: Spectral AI, Inc. is an emerging growth company incorporated in Delaware, developing AI-driven burn wound technology known as the DeepView® System. The company's common stock and redeemable warrants trade on The Nasdaq Stock Market LLC under the symbols MDAI and MDAIW, respectively.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain comprehensive financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the period.
Material Changes
The primary material event reported is the award of $31.7 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). This funding is designated to accelerate and support additional feature aspects for the company's DeepView® System.
Guidance, Outlook, and Management Commentary
- Management Commentary: The company issued a press release (Exhibit 99.1) announcing the BARDA funding award.
- Outlook: The funding is intended to advance the development of the DeepView® System, indicating a strategic focus on expanding the capabilities of its AI-driven burn wound technology.
- Risks and Contingencies: The filing includes standard disclaimers stating that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the terms and conditions of the $31.7 million BARDA funding agreement, including any milestones or repayment obligations.
- Review the full text of the press release (Exhibit 99.1) for specific details on how the funding will be allocated to the DeepView® System.
- Confirm the company's cash runway and burn rate in subsequent periodic reports (10-Q or 10-K) to assess the impact of this funding on liquidity.
- Monitor regulatory approvals required for the DeepView® System features being developed with this funding.